We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood

By LabMedica International staff writers
Posted on 21 Apr 2021
A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma.

Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. More...
Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.

While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.

In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.

Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.

"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."

The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.

Related Links:
Walter Reed Army Institute for Research


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.